v3.26.1
Reverse Recapitalization and Sonnet Acquisition (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2026
Jul. 11, 2025
Mar. 31, 2026
Dec. 02, 2025
Jul. 02, 2025
Jun. 30, 2025
Business Combination [Line Items]            
Common stock, par or stated value per share $ 0.01   $ 0.01   $ 0.01 $ 0.01
Stock issued during period, value, new issues     $ 1,470      
Asset Purchase Agreement [Member]            
Business Combination [Line Items]            
cash transactions $ 1,325   1,325      
deferred purchase price 1,000   $ 1,000      
Services fees expense $ 175          
Common Stock [Member]            
Business Combination [Line Items]            
Common stock, par or stated value per share       $ 0.01    
Stock issued during period, shares, new issues     252,600      
Stock issued during period, value, new issues     $ 3      
Rorschach Advisors LLC [Member]            
Business Combination [Line Items]            
Number of cryptocurrency token   12.5        
Cryptocurrency token value   $ 411,300        
Loss on commitment on cryptocurrency token   $ 169,200        
Rorschach Advisors LLC [Member] | Common Stock [Member]            
Business Combination [Line Items]            
Common stock, par or stated value per share   $ 1.25        
Stock issued during period, shares, new issues   7,761,860        
Rorschach and Sonnet Merger [Member]            
Business Combination [Line Items]            
Number of cryptocurrency token   12.5        
Rorschach and Sonnet Merger [Member] | Common Stock [Member]            
Business Combination [Line Items]            
Stock issued during period, value, new issues   $ 299,900        
Sonnet BioTherapeutics Holdings, Inc. [Member]            
Business Combination [Line Items]            
Stock issued during period, shares, new issues   3,680,346        
Stock issued during period, value, new issues   $ 17,800        
Total cost of the acquisition   44,834        
Transaction costs   9,324        
Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]            
Business Combination [Line Items]            
Stock issued during period, value, new issues   $ 17,771        
Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member]            
Business Combination [Line Items]            
Stock issued during period, shares, new issues   2,400,000        
Stock issued during period, value, new issues   $ 12,478        
Cash payment to settle outstanding warrants   $ 5,261        
Guidant Bio Therapeutics Inc. [Member] | Asset Purchase Agreement [Member]            
Business Combination [Line Items]            
percentage of common stock interest 40.00%   40.00%